Q4 Earnings Forecast for Novartis Issued By Zacks Research

Key Points

• Zacks Research raised its Q4 2026 EPS forecast for Novartis to $2.21 from $2.20, while estimating full-year 2026 EPS at $8.85 and 2027 EPS at $9.68.
• Novartis shares were trading up 1.3% at $160.09, near their 12-month high of $170.46, giving the company a market capitalization of approximately $305.5 billion.
• Analyst sentiment remains mixed: seven analysts rate the stock Buy, seven Hold and two Sell, resulting in an overall “Hold” rating and an average price target of $141.20.

Novartis AG (NYSE:NVS - Free Report) - Zacks Research upped their Q4 2026 earnings per share (EPS) estimates for Novartis in a note issued to investors on Monday, August 24th. Zacks Research analyst Team now expects that the company will post earnings of $2.21 per share for the quarter, up from their prior forecast of $2.20. The consensus estimate for Novartis' current full-year earnings is $8.85 per share. Zacks Research also issued estimates for Novartis' Q3 2027 earnings at $2.45 EPS, FY2027 earnings at $9.68 EPS and Q1 2028 earnings at $2.55 EPS.

NVS has been the topic of several other research reports. Weiss Ratings reissued a "buy (b)" rating on shares of Novartis in a research note on Friday, July 24th. Citigroup reaffirmed a "buy" rating on shares of Novartis in a research report on Wednesday, July 22nd. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $141.20.

Novartis Trading Up 1.3%

Shares of NYSE NVS opened at $160.09 on Wednesday. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $305.47 billion, a PE ratio of 24.15, a PEG ratio of 2.71 and a beta of 0.45. Novartis has a twelve month low of $121.57 and a twelve month high of $170.46. The stock has a fifty day simple moving average of $154.66 and a 200-day simple moving average of $153.77.

Novartis (NYSE:NVS - Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The company had revenue of $14.95 billion for the quarter.

Hedge Funds Weigh In On Novartis

A number of institutional investors and hedge funds have recently modified their holdings of NVS. Highland Investment Advisors LLC purchased a new stake in Novartis during the 2nd quarter worth about $25,000. Evolution Wealth Management Inc. increased its holdings in shares of Novartis by 552.0% in the 2nd quarter. Evolution Wealth Management Inc. now owns 163 shares of the company's stock valued at $26,000 after acquiring an additional 138 shares during the last quarter. Atlatl Advisers LLC purchased a new position in shares of Novartis in the 2nd quarter valued at about $26,000. Archer Investment Corp raised its position in shares of Novartis by 93.0% during the 1st quarter. Archer Investment Corp now owns 166 shares of the company's stock worth $25,000 after acquiring an additional 80 shares in the last quarter. Finally, Arlington Trust Co LLC acquired a new stake in shares of Novartis during the 4th quarter worth about $25,000. Institutional investors and hedge funds own 13.12% of the company's stock.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company's activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source